ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,237.72
-0.42%
Dow Jones
39,150.33
0.04%
Gold vs US Dollar
2,322.29
-1.64%
Brent Oil
84.435
-0.67%
Bitcoin
64,254.87
-0.87%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Boundless Bio Inc (BOLD)

  7. Boundless Bio Inc (BOLD) News

Boundless Bio (BOLD)

Boundless Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BOLD
DateTimeSourceHeadlineSymbolCompany
05/06/202412:00Business WireBoundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:BOLDBoundless Bio Inc
13/05/202412:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLDBoundless Bio Inc
13/05/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLDBoundless Bio Inc
13/05/202412:00Business WireBoundless Bio Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BOLDBoundless Bio Inc
06/05/202413:00Business WireBoundless Bio to Present at the Citizens JMP Life Sciences Conference 2024NASDAQ:BOLDBoundless Bio Inc
11/04/202413:00Business WireBoundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsNASDAQ:BOLDBoundless Bio Inc
08/04/202413:00Business WireBoundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024NASDAQ:BOLDBoundless Bio Inc
14/02/202022:23Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BOLDBoundless Bio Inc
14/02/202021:35Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BOLDBoundless Bio Inc
14/02/202021:15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BOLDBoundless Bio Inc
11/02/202021:41Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:BOLDBoundless Bio Inc
05/02/202016:27Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BOLDBoundless Bio Inc
27/01/202014:38Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:BOLDBoundless Bio Inc
21/01/202011:00Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BOLDBoundless Bio Inc
21/01/202011:00Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BOLDBoundless Bio Inc
04/12/201900:13PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.NASDAQ:BOLDBoundless Bio Inc
02/12/201923:01Business WireAstellas Enters into Definitive Agreement to Acquire Audentes TherapeuticsNASDAQ:BOLDBoundless Bio Inc
26/11/201921:01Business WireAudentes Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:BOLDBoundless Bio Inc
12/11/201922:33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BOLDBoundless Bio Inc
12/11/201917:13Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BOLDBoundless Bio Inc
07/11/201922:18Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BOLDBoundless Bio Inc
07/11/201921:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BOLDBoundless Bio Inc
07/11/201921:01Business WireAudentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:BOLDBoundless Bio Inc
31/10/201911:00Business WireAudentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2...NASDAQ:BOLDBoundless Bio Inc
09/10/201911:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BOLDBoundless Bio Inc
05/10/201912:01Business WireAudentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked M...NASDAQ:BOLDBoundless Bio Inc
04/10/201923:00Business WireAudentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BOLDBoundless Bio Inc
01/10/201913:00Business WireAudentes Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:BOLDBoundless Bio Inc
30/09/201913:00Business WireAudentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including Ne...NASDAQ:BOLDBoundless Bio Inc
25/09/201923:12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BOLDBoundless Bio Inc
 Showing the most relevant articles for your search:NASDAQ:BOLD

Your Recent History

UNSW3
BNOXUSDT
BlockNoteX
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved